News Briefs: Biomet IPO; Hep C Screening Coverage; Valve Guidelines
This article was originally published in The Gray Sheet
Biomet’s parent company filed an initial public offering registration statement for the firm March 7. CMS proposes national coverage for hepatitis C screening. ACC and AHA release new heart valve guidelines. More news.
You may also be interested in...
The firm announced Oct. 29 an agreement with Apollo Endosurgery to sell its obesity intervention business, including the Lap-Band adjustable band.
Hepatitis C virus screening national coverage supported in comments. Proposed decision memo delayed for percutaneous image-guided lumbar decompression for lumbar spinal stenosis national coverage determination. More reimbursement news.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.